At a Glance
Quickcomparison
Dose Range
Urocortin
As prescribed–As prescribed mg
BPC-157
250–500 mcg
Frequency
Once daily
Administration
As directed by healthcare provider
Subcutaneous injection
Cycle Length
Ongoing/indefinite
4-6 weeks
Onset Speed
Moderate (1-2 weeks)
Evidence Level
Moderate human trials (Phase 1-2)
Strong preclinical (extensive animal studies)
Efficacy
Benefitratings
Cardiovascular Protection
Stress Response & Resilience
Heart Function Support
Primary Benefit
Secondary Benefit
Additional Benefit
Technical Data
Compoundspecifications
Molecular Formula
C216H329N59O64S
Molecular Weight
Approximately 4,700 Daltons
Half-Life
Approximately 2-6 hours (varies by route of administration)
Bioavailability
Varies by route of administration
CAS Number
173190-76-4
C62H98N16O22
1419.53 g/mol
4-6 hours
~100% (subcutaneous)
137525-51-0
Protocols
Dosingtiers
starting
5 ng/kg/min (urocortin-2)
Continuous infusion
4 hours
Adjunct dose used in the UNICORN study of 53 acute decompensated heart failure patients [6]. Investigational only.
standard
Urocortin-2 36–360 pmol/min or urocortin-3 1.2–12 nmol/min (ascending)
Incremental infusion
Per study protocol
Ascending IV doses studied in chronic heart failure patients; increased cardiac index and reduced vascular resistance [7]. Research use only — no approved product.
250 mcg
1-2 weeks
A common starting amount in research practice, often injected near the injured area. BPC-157 has no human dose-finding trials, so doses come from animal studies and documented practice [1][2].
250-500 mcg
Twice daily
Commonly used range for tissue and tendon recovery in research practice [1][3].
advanced
500 mcg
6-8 weeks
Upper end used in practice for more demanding acute injuries [1][3].
Applications
Bestsuited for
Supporting cardiovascular health during stressful periods
Urocortin is particularly well-suited for individuals focused on supporting cardiovascular health during stressful periods. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Improving heart function in those with weakened hearts
Urocortin is particularly well-suited for individuals focused on improving heart function in those with weakened hearts. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Enhancing stress resilience and coping
Urocortin is particularly well-suited for individuals focused on enhancing stress resilience and coping. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Optimizing blood vessel and circulation function
Urocortin is particularly well-suited for individuals focused on optimizing blood vessel and circulation function. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Tendon and ligament injuries
Sprains, strains, tears, tendinitis - BPC-157 accelerates collagen synthesis and tissue repair
Gut healing
IBS, leaky gut, ulcers, inflammatory bowel conditions - derived from gastric juice, it has a natural affinity for digestive tissue
Muscle injuries
Strains, post-workout recovery, chronic muscle issues - promotes angiogenesis and growth factor expression
Joint problems
Arthritis support, joint pain, cartilage issues - anti-inflammatory and regenerative properties
Post-surgical recovery
Accelerating healing after procedures - works systemically to enhance the body's repair mechanisms
Safety Profile
Sideeffects
Common
Facial flushing
Mild headache
Dizziness
Injection site response
Nausea
Serious
Severe allergic reaction
Severe blood pressure changes
Heart palpitations
Injection site redness
Mild nausea
Uncommon
Headache
Fatigue
Hot/cold sensations
Allergic reaction
Research Status
Safety& evidence
FDA Status
Research compound
Safety Overview
Urocortin III (a corticotropin-releasing factor analogue) shows preclinical safety in animal models with potential CNS and cardiovascular effects through CRF receptor activation. No completed human clinical trials exist—all human data comes from limited Phase 1 safety/tolerability work in small populations. Expected adverse effects based on CRF physiology include anxiety/panic-like symptoms (paradoxical, due to CRF's role in stress response), hypothalamic-pituitary-adrenal (HPA) axis effects, and cardiovascular responses (blood pressure, heart rate changes). Neurotoxicity and excitotoxicity are theoretical concerns requiring electrolyte and cardiac monitoring.
Contraindications
xHypersensitivity to urocortin or CRF-related peptides
xSevere hypertension without medical monitoring
xAcute coronary syndrome (heart attack) - requires careful evaluation
xUncontrolled arrhythmias
xPregnancy and breastfeeding (limited safety data)
BPC-157 is a gastric pentadecapeptide with strong preclinical evidence from extensive animal studies spanning over 25 years of research. Critical limitation: BPC-157 has NOT completed Phase 3 human clinical trials. No FDA approval exists. Safety data comes primarily from rat and mouse studies, with only limited Phase 1-2 human data. Animal studies show no toxicity at therapeutic doses, but human data is insufficient for regulatory approval. The peptide is unregulated, and no standardized manufacturing or quality control requirements exist for research compounds. Individual responses may vary significantly, and serious medical supervision is essential before use, particularly if you have gastrointestinal conditions, take medications, or have pre-existing medical conditions.
xPregnancy
xBreastfeeding
xActive cancer
xHistory of cancer
Decision Guide
Which isright for you?
Choose Urocortin if...
Supporting cardiovascular health during stressful periods
Improving heart function in those with weakened hearts
Enhancing stress resilience and coping
Optimizing blood vessel and circulation function
Choose BPC-157 if...
Injury recovery
Post-surgery healing
Chronic pain management
Gut health